NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01161316,Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours,https://clinicaltrials.gov/study/NCT01161316,MACRO-2,COMPLETED,The purpose of the study is to evaluate the efficacy and safety of the combination of mFOLFOX-6 plus cetuximab for 8 cycles followed by mFOLFOX-6 plus cetuximab or single agent (s/a) cetuximab as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC).,NO,Metastatic Colorectal Cancer,"DRUG: mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|DRUG: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.","progression-free survival, 2010-2014","overall survival, 2010-2014|rate of objective responses, 2010-2014|disease's resectability (R0), 2010-2014|evaluate hypomagnesaemia as a predictive factor in the treatment's efficacy, 2010-2014|Adverse events, 2010-2014",,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),,ALL,"ADULT, OLDER_ADULT",PHASE2,194,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,TTD-09-04|2009-017194-38,2010-08,2015-06,2015-06,2010-07-13,,2015-07-27,"Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, 28046, Spain",
